Targeting CRYβB2 and CRYβB2P1 may assist in reducing the disparate survival outcomes observed between Black and White American breast cancer patients, or may better identify those patients most at risk for more aggressive disease. This evidence concerns the gene CRYBB2P1 and breast carcinoma.